[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506797":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":208,"collaborators":21,"id":210,"slug":211,"hasResults":212,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":21,"eligibilityCriteria":216,"healthyVolunteers":212,"sex":217,"minAge":218,"maxAge":21,"enrollmentInfo":219,"targetDuration":21,"studyType":222,"phases":223,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":39,"whyStopped":21,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},{"fullName":5,"class":6},"Biotheus Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PM8002+FOLFIRI","EXPERIMENTAL","Subjects will be administered with PM8002 plus FOLFIRI via intravenously (IV) Q2W until disease progression or intolerable toxicity for a maximum of 2 years.",[13,14],"Drug: PM8002","Drug: FOLFIRI",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","PM8002","IV infusion",[9],null,{"type":17,"name":23,"description":19,"armGroupLabels":24,"otherNames":21},"FOLFIRI",[9],[26],{"name":27,"affiliation":28,"role":29},"Jianming Xu","Chinese PLA General Hospital","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":21,"email":35},"Jia Song","CONTACT","+86 15921737659","song.j@biotheus.com",[37,54,67,80,93,106,118,131,143,159,172,185,196],{"facility":38,"status":39,"city":40,"state":41,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Chongqing University Cancer Hospital","RECRUITING","Chongqing","Chongqing Municipality","China","CN",{"type":45,"coordinates":46},"Point",[47,48],106.55771,29.56026,{"lat":48,"lon":47},[51,53],{"name":52,"role":33,"phone":21,"phoneExt":21,"email":21},"Yan Li",{"name":52,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":55,"status":39,"city":56,"state":57,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Fujian Province Cancer Hospital","Fuzhou","Fujian",{"type":45,"coordinates":59},[60,61],119.30611,26.06139,{"lat":61,"lon":60},[64,66],{"name":65,"role":33,"phone":21,"phoneExt":21,"email":21},"Jianwei Yang",{"name":65,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":68,"status":39,"city":69,"state":70,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Harbin Medical University Cancer Hospital","Harbin","Heilongjiang",{"type":45,"coordinates":72},[73,74],126.65,45.75,{"lat":74,"lon":73},[77,79],{"name":78,"role":33,"phone":21,"phoneExt":21,"email":21},"Yuxian Bai",{"name":78,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":81,"status":39,"city":82,"state":83,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan",{"type":45,"coordinates":85},[86,87],113.64861,34.75778,{"lat":87,"lon":86},[90,92],{"name":91,"role":33,"phone":21,"phoneExt":21,"email":21},"Lijie Song",{"name":91,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":94,"status":39,"city":95,"state":96,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Jingzhou First People's Hospital","Jingzhou","Hubei",{"type":45,"coordinates":98},[99,100],112.19028,30.35028,{"lat":100,"lon":99},[103,105],{"name":104,"role":33,"phone":21,"phoneExt":21,"email":21},"Jun Cai",{"name":104,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":107,"status":39,"city":108,"state":96,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Union Hospital Tongji Medical College of Hust","Wuhan",{"type":45,"coordinates":110},[111,112],114.26667,30.58333,{"lat":112,"lon":111},[115,117],{"name":116,"role":33,"phone":21,"phoneExt":21,"email":21},"Hongli Liu",{"name":116,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":119,"status":39,"city":120,"state":121,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Hunan Cancer Hospital","Changsha","Hunan",{"type":45,"coordinates":123},[124,125],112.97087,28.19874,{"lat":125,"lon":124},[128,130],{"name":129,"role":33,"phone":21,"phoneExt":21,"email":21},"Zhenyang Liu",{"name":129,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":132,"status":39,"city":133,"state":121,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"The Central Hospital of Yongzhou","Yongzhou",{"type":45,"coordinates":135},[136,137],111.61306,26.42389,{"lat":137,"lon":136},[140,142],{"name":141,"role":33,"phone":21,"phoneExt":21,"email":21},"Pengfei Luo",{"name":141,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":144,"status":39,"city":145,"state":146,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Nanjing Drum Tower Hospital","Nanjing","Jiangsu",{"type":45,"coordinates":148},[149,150],118.77778,32.06167,{"lat":150,"lon":149},[153,155,157,158],{"name":154,"role":33,"phone":21,"phoneExt":21,"email":21},"Baorui Liu",{"name":156,"role":33,"phone":21,"phoneExt":21,"email":21},"Qin Liu",{"name":154,"role":29,"phone":21,"phoneExt":21,"email":21},{"name":156,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":160,"status":39,"city":161,"state":162,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Shandong Cancer Hospital","Jinan","Shandong",{"type":45,"coordinates":164},[165,166],116.99722,36.66833,{"lat":166,"lon":165},[169,171],{"name":170,"role":33,"phone":21,"phoneExt":21,"email":21},"Zuoxing Niu",{"name":170,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":173,"status":39,"city":174,"state":175,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University)","Kunming","Yunnan",{"type":45,"coordinates":177},[178,179],102.71833,25.03889,{"lat":179,"lon":178},[182,184],{"name":183,"role":33,"phone":21,"phoneExt":21,"email":21},"Lin Xie",{"name":183,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":28,"status":39,"city":186,"state":21,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Beijing",{"type":45,"coordinates":188},[189,190],116.39723,39.9075,{"lat":190,"lon":189},[193,195],{"name":27,"role":33,"phone":21,"phoneExt":21,"email":194},"Jianmingxu2014@163.com",{"name":27,"role":29,"phone":21,"phoneExt":21,"email":21},{"facility":197,"status":39,"city":198,"state":21,"zip":21,"country":42,"countryCode":43,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"ZhongShan Hospital Fudan University","Shanghai",{"type":45,"coordinates":200},[201,202],121.45806,31.22222,{"lat":202,"lon":201},[205,207],{"name":206,"role":33,"phone":21,"phoneExt":21,"email":21},"Tianshu Liu",{"name":206,"role":29,"phone":21,"phoneExt":21,"email":21},{"type":209,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100506797","phase-2-a-study-of-pm8002-in-combination-with-chemotherapy-in-patients-with-nen-100506797",false,"NCT05879055","A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm","Inclusion Criteria:\n\n1. Signed informed consent form before any trial-related processes;\n2. Aged ≥ 18 years;\n3. Ki-67≥55% G3 NET and NEC were confirmed histologically or cytologically by pathological diagnosis in this study;\n4. Subjects failed first-line platinum-based chemotherapy;\n5. Adequate organ function;\n6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;\n7. Expected survival ≥ 12 weeks;\n8. Had at least one measurable tumor lesion according to RECIST v1.1;\n\nExclusion Criteria:\n\n1. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;\n2. Evidence and history of severe bleeding tendency;\n3. History of severe cardiovascular diseases within 6 months;\n4. Subjects should provide formalin-fixed-paraffin-embedded (FFPE) tumor samples during the screening period (up to 24 months);\n5. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;\n6. History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation;\n7. History of alcohol abuse, psychotropic substance abuse or drug abuse;\n8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome;\n9. Pregnant or lactating women;\n10. Other conditions considered unsuitable for this study by the investigator.","ALL","18 Years",{"count":220,"type":221},60,"ESTIMATED","INTERVENTIONAL",[224],"PHASE2","PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).",[227],"Neuroendocrine Neoplasm",[229,230,231],"Second line","NEC","G3 NET","2024-12-17",{"date":234,"type":235},"2024-12-19","ACTUAL",{"date":237,"type":235},"2023-05-17",{"date":239,"type":221},"2028-01-01",{"name":5,"class":6},13]